科研之友
微信
新浪微博
Facebook
分享链接
摘要
Recent epidemiologic studies attempting to demonstrate the risk of kidney diseases among patients using proton pump inhibitors (PPIs) have been conflicting. The aim of this meta-analysis was to summarize all available evidence. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases, as well as reference lists of relevant articles, were searched to identify observational studies reporting odd ratios or hazard ratios comparing the risk of kidney diseases in patients with PPIs use. A random-effects model was used to pool study-specific risk estimates. A total of 9 articles, including 10 studies (n = 2,484,924 participants), were eventually identified in this meta-analysis. Compared with patients that did not use PPIs, pooled risk ratios (RR) for patients with kidney diseases including acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD), and end stage renal disease (ESRD) were 3.76 (95% CI, 2.36-5.99), 1.61 (95% CI, 1.16-2.22), 1.20 (95% CI, 1.09-1.32), and 1.88 (95% CI, 1.72-2.06), respectively. PPIs are associated with increased risk of AIN, AKI, CKD, and ESRD. Future investigations are encouraged to reveal the underlying mechanisms connecting PPIs use and kidney diseases, perhaps stimulating the development of more effective preventive and therapeutic measures.
